A Phase I clinical trial investigating immunisation strategies using DNA, MVA and CN54rgp140 adjuvanted with GLA-AF to maximise antibody responses.
Studying whether combining two components of a combination vaccine can improve immune responses amd reduce the number of shots those with HIV need
What is this study about?
There is currently no cure for HIV and although treatment is available, it is inaccessible to many, has to be taken for life and can be associated with side effects. It is widely accepted that a vaccine for HIV would be the best way to prevent infection and although there has been one encouraging trial in Thailand, there is currently no vaccine available.
We are exploring a strategy using a combination of three different types of vaccine. This approach has previously been shown to be more efficient than just a single component. There is currently great interest in whether combining vaccines could improve their performance.
In this study half (20) the volunteers will receive 7 vaccinations and the other half will receive 5. We will follow up everyone in the same way and are interested in immune responses and also whether there are any reactions to the vaccinations.
This study is one of several that we are involved in using common vaccines and so we will be able to directly compare the results across these studies in order to optimise the design of the next (larger) clinical study.
Type of study
Who is funding the study?
The Medical Research Council.
When is it taking place?
Where is it taking place?
St Marys Hospital, London, Surrey Clinical Research Centre, Guildford
Who is included?
40 healthy adult men and women aged 18-45 at low risk of HIV infection.